These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
765 related articles for article (PubMed ID: 33212418)
1. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index. Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418 [TBL] [Abstract][Full Text] [Related]
2. Predictive ability of a drug-based score in patients with advanced non-small-cell lung cancer receiving first-line immunotherapy. Buti S; Bersanelli M; Perrone F; Bracarda S; Di Maio M; Giusti R; Nigro O; Cortinovis DL; Aerts JGJV; Guaitoli G; Barbieri F; Ferrara MG; Bria E; Grossi F; Bareggi C; Berardi R; Torniai M; Cantini L; Sforza V; Genova C; Chiari R; Rocco D; Della Gravara L; Gori S; De Tursi M; Di Marino P; Mansueto G; Zoratto F; Filetti M; Citarella F; Russano M; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Follador A; Bisonni R; Tuzi A; Minuti G; Landi L; Ricciardi S; Migliorino MR; Tabbò F; Olmetto E; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Addeo A; Friedlaender A; Cannita K; Porzio G; Ficorella C; Carmisciano L; Pinato DJ; Mazzaschi G; Tiseo M; Cortellini A Eur J Cancer; 2021 Jun; 150():224-231. PubMed ID: 33934059 [TBL] [Abstract][Full Text] [Related]
3. Differential influence of antibiotic therapy and other medications on oncological outcomes of patients with non-small cell lung cancer treated with first-line pembrolizumab versus cytotoxic chemotherapy. Cortellini A; Di Maio M; Nigro O; Leonetti A; Cortinovis DL; Aerts JG; Guaitoli G; Barbieri F; Giusti R; Ferrara MG; Bria E; D'Argento E; Grossi F; Rijavec E; Guida A; Berardi R; Torniai M; Sforza V; Genova C; Mazzoni F; Garassino MC; De Toma A; Signorelli D; Gelibter A; Siringo M; Marchetti P; Macerelli M; Rastelli F; Chiari R; Rocco D; Della Gravara L; Inno A; Michele T; Grassadonia A; Di Marino P; Mansueto G; Zoratto F; Filetti M; Santini D; Citarella F; Russano M; Cantini L; Tuzi A; Bordi P; Minuti G; Landi L; Ricciardi S; Migliorino MR; Passiglia F; Bironzo P; Metro G; Adamo V; Russo A; Spinelli GP; Banna GL; Friedlaender A; Addeo A; Cannita K; Ficorella C; Porzio G; Pinato DJ J Immunother Cancer; 2021 Apr; 9(4):. PubMed ID: 33827906 [TBL] [Abstract][Full Text] [Related]
4. Do proton pump inhibitors alter the response to immune checkpoint inhibitors in cancer patients? A meta-analysis. Lopes S; Pabst L; Dory A; Klotz M; Gourieux B; Michel B; Mascaux C Front Immunol; 2023; 14():1070076. PubMed ID: 36776847 [TBL] [Abstract][Full Text] [Related]
5. Characterization of outcomes in patients with advanced genitourinary malignancies treated with immune checkpoint inhibitors. Ma VT; Su CT; Hu M; Taylor JMG; Daignault-Newton S; Kellezi O; Dahl MN; Shah MA; Erickson S; Lora J; Hamasha R; Ali A; Yancey S; Kiros L; Balicki HM; Winfield DC; Green MD; Alva AS Urol Oncol; 2021 Jul; 39(7):437.e1-437.e9. PubMed ID: 33495117 [TBL] [Abstract][Full Text] [Related]
6. How to Choose a Survival Period? The Impact of Antibiotic Use on OS or PFS in NSCLC Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. Chen H; Han KD; He ZJ; Huang YS Technol Cancer Res Treat; 2021; 20():15330338211033498. PubMed ID: 34323149 [TBL] [Abstract][Full Text] [Related]
7. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors. Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C Front Immunol; 2021; 12():716317. PubMed ID: 34777340 [TBL] [Abstract][Full Text] [Related]
9. Antibiotics are associated with attenuated efficacy of anti-PD-1/PD-L1 therapies in Chinese patients with advanced non-small cell lung cancer. Zhao S; Gao G; Li W; Li X; Zhao C; Jiang T; Jia Y; He Y; Li A; Su C; Ren S; Chen X; Zhou C Lung Cancer; 2019 Apr; 130():10-17. PubMed ID: 30885328 [TBL] [Abstract][Full Text] [Related]
10. Prognosis stratification of cancer patients treated with immune checkpoint inhibitors through lung immune prognostic index: a meta-analysis and systematic review. Guo Y; Pan Y; Wan J; Gong B; Li Y; Kan X; Zheng C BMC Cancer; 2024 Apr; 24(1):523. PubMed ID: 38664760 [TBL] [Abstract][Full Text] [Related]
11. Effect of cyclo-oxygenase inhibitor use during checkpoint blockade immunotherapy in patients with metastatic melanoma and non-small cell lung cancer. Wang SJ; Khullar K; Kim S; Yegya-Raman N; Malhotra J; Groisberg R; Crayton SH; Silk AW; Nosher JL; Gentile MA; Mehnert JM; Jabbour SK J Immunother Cancer; 2020 Oct; 8(2):. PubMed ID: 33020239 [TBL] [Abstract][Full Text] [Related]
12. The impact of antibiotics on efficacy of immune checkpoint inhibitors in malignancies: A study based on 44 cohorts. Wu Q; Liu J; Wu S; Xie X Int Immunopharmacol; 2021 Mar; 92():107303. PubMed ID: 33465728 [TBL] [Abstract][Full Text] [Related]
13. Combination of alpha-fetoprotein and neutrophil-to-lymphocyte ratio to predict treatment response and survival outcomes of patients with unresectable hepatocellular carcinoma treated with immune checkpoint inhibitors. Zhu HF; Feng JK; Xiang YJ; Wang K; Zhou LP; Liu ZH; Cheng YQ; Shi J; Guo WX; Cheng SQ BMC Cancer; 2023 Jun; 23(1):547. PubMed ID: 37322411 [TBL] [Abstract][Full Text] [Related]
14. Impact of Proton Pump Inhibitor Use on the Effectiveness of Immune Checkpoint Inhibitors in Advanced Cancer Patients. Peng K; Chen K; Teply BA; Yee GC; Farazi PA; Lyden ER Ann Pharmacother; 2022 Apr; 56(4):377-386. PubMed ID: 34282636 [TBL] [Abstract][Full Text] [Related]
15. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia. Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621 [TBL] [Abstract][Full Text] [Related]
16. Survival outcomes of patients with nonsmall cell lung cancer concomitantly receiving proton pump inhibitors and immune checkpoint inhibitors. Baek YH; Kang EJ; Hong S; Park S; Kim JH; Shin JY Int J Cancer; 2022 Apr; 150(8):1291-1300. PubMed ID: 34877670 [TBL] [Abstract][Full Text] [Related]
17. Adverse impact of bone metastases on clinical outcomes of patients with advanced non-small cell lung cancer treated with immune checkpoint inhibitors. Li X; Wang L; Chen S; Zhou F; Zhao J; Zhao W; Su C Thorac Cancer; 2020 Oct; 11(10):2812-2819. PubMed ID: 32779372 [TBL] [Abstract][Full Text] [Related]
18. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data. Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328 [TBL] [Abstract][Full Text] [Related]
19. Association between immune-related side effects and efficacy and benefit of immune checkpoint inhibitors - A systematic review and meta-analysis. Hussaini S; Chehade R; Boldt RG; Raphael J; Blanchette P; Maleki Vareki S; Fernandes R Cancer Treat Rev; 2021 Jan; 92():102134. PubMed ID: 33302134 [TBL] [Abstract][Full Text] [Related]
20. Impact of concurrent medications on the outcome of immunotherapy in non-small cell lung carcinoma. Yamada J; Fukui T; Yatani A; Mimura C; Fukuda K; Hazama D; Katsurada N; Nagano T; Yamamoto M; Tachihara M Thorac Cancer; 2024 May; 15(15):1228-1236. PubMed ID: 38622898 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]